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Background: The role of breast milk on the risk of childhood asthma is in dispute. The aim of this prospective
study is to determine the relationship of immune markers in maternal serum during gestation and breast milk to
asthma-like symptoms (AS) in infancy.
Methods: Pregnant women were recruited in Columbia and Charleston, South Carolina. Blood (median: three weeks
before delivery) and breast milk (three weeks after delivery) samples were collected. Concentrations of interferon (IFN)-γ,
IFN gamma-induced protein 10 (IP-10 or CXCL10), CCL11, interleukin (IL) 1β, IL-4, IL-5, IL-6, CXCL8, IL-10, IL-12(p70), IL-13,
transforming growth factor (TGF)-β1, and immunoglobulin (Ig) A in both maternal serum and milk whey were
determined via immunoassays. Asthma-like symptoms (AS) of the infant were ascertained at 6 and 12 months,
respectively. Generalized estimating equations assessed relative risks (RRs) of immune markers for repeated measurements
of AS, considering intra-individual correlations and adjusting for confounders. To provide comparable risk estimates,
quartiles of the immune markers were used, except for IL-5 in whey and IgA in serum, which were dichotomized.
Results: Of 178 women, 161 provided blood and 115 breast milk samples. IL-12(p70), IL-4, IL-10, IL-1β, and CCL11 in
serum and in whey were not further considered for the statistical analyses since the proportion of non-detectable values
was high. Most immune markers in serum and milk whey were moderately or highly correlated; however, IgA was
negatively correlated. Infants in the highest quartile of IL-13 in both serum and whey were at a higher risk of AS (RR=3.02
and 4.18; respectively) compared to infants in the first quartile. High levels of IL-5 in serum and whey was also identified
as a risk. In addition, increased secretory IgA and TGF-β1 in breast milk reduced the risks of AS.
Conclusions: Maternal serum and whey levels of IL-5 and IL-13 are risk markers for AS; whey IgA and TGF-β1 seem to be
protective. Only focusing on breast milk portend that milk cytokines IL-5 and IL-13 have adverse effects. However, similar
immune exposures during late gestation and via milk suggest that both may enhance AS among infants.
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Allergic disorders such as eczema, asthma, and hay fever
are among the most common chronic diseases during
childhood [1]. In the United States, more than 10 mil-
lion children under 18 years of age have ever been diag-
nosed with asthma (14%); almost 7 million children have
ongoing asthma (10%) [2]. The socioeconomic burden of
asthma is striking [3]. Despite considerable progress in
research, an understanding of the etiology of childhood
asthma remains incomplete. Breast milk contains a var-
iety of immune molecules such as immunoglobulins,
cytokines, chemokines, and growth factors, which are
believed to protect the infant from common pathogens.
There is a consensus of a protective effect of breastfeed-
ing on lowering the risk or severity of respiratory infec-
tions [4,5]. However, for asthma, the question of
whether breastfeeding is protective or a risk remains
controversial. Some studies report that exclusive breast-
feeding is associated with a reduced risk [6-14], while
others report an increased risk of asthma [15,16] or no
association [17-19].
Breast milk related factors that are responsible for a
potential association with asthma risk have not yet been
clearly identified. Immune markers, particularly, the T
helper (Th)1/Th2/Th3/T-regulatory pathways are thought
to be critical players. Th1 cells are responsible for cell-
mediated immunity and phagocyte-dependent protective
responses, while Th2 cells are associated with antibody pro-
duction, eosinophil activation, and inhibition of several
macrophage functions [20]. Studies reported that cytokines
and chemokines related to eosinophil activation (such as
IL-5, CCL11) and production of immunoglobulin E (such
as IL-4, IL-13) are responsible for allergies in children
[21,22].
Past studies have focused on breast milk and asthma-
like symptoms (AS) in infancy but ignored whether
maternal immune response may influence the fetal
immune system. The aim of the longitudinal study is to
determine whether different proteins in breast milk
whey and maternal serum before delivery are linked
to AS in infants at ages 6 and 12 months. We focused
on levels of Type-1/pro-inflammatory cytokines/chemo-
kines (interferon (IFN)-γ, interferon gamma-induced
protein 10 (IP-10 or CXCL10), interleukin (IL)-1β, IL-6,
IL-12(p70), CXCL8 (IL-8)), Type-2/pro-allergic cytokines/
chemokines (IL-4, IL-5, IL-13, and CCL11 (eotaxin)),
T-regulatory/anti-inflammatory cytokines (transforming
growth factor (TGF)-β1 and IL-10), and the secretory im-
munoglobulin A (IgA).
Methods
This investigation was derived from two ongoing longi-
tudinal studies, which were approved by the University
of South Carolina Institutional Review Boards, theMedical University of South Carolina, and the Palmetto
Health Institutional Review Boards for Human Subjects.
All participants signed a written consent form either in
English or Spanish.
Participants
Expecting mothers in the second trimester were enrolled
between April 2008 and January 2010 in Columbia and
Charleston, South Carolina, in prenatal clinics and pre-
natal classes. Trained staff recruiters invited the expect-
ing mothers to participate in the study at the prenatal
classes and by research nurses performed recruitment
tasks at the prenatal clinics. Eligibility criteria included:
(1) aged 18 years or older, (2) no chronic illness (dia-
betes, thyroid or adrenal disorders, or chronic infec-
tions), (3) planned to stay in the area for at least nine
months, and (4) willingness to provide a breast milk
sample two weeks after delivery.
Questionnaires and potential confounders
Women took part in four telephone or in-person inter-
views: a core demographic and baseline interview con-
ducted before delivery, and three interviews at 2 weeks,
and 6 and 12 months after delivery, respectively. At the
baseline interview, information was obtained about
women’s socio-demographic and medical factors includ-
ing race (African American, Caucasian or other), mater-
nal age, maternal and household smoking during
pregnancy period (yes, no), education level (less than
high school, some college, college graduate, or graduate
school), and maternal history of allergy (eczema, asthma,
and rhinitis). The maternal history of asthma, wheezing
and whistling in the chest, and eczema was obtained by
asking: “Have you ever had asthma?” and “Have you ever
had wheezing or whistling in the chest at any time in
the past?” The next two questions were grouped to de-
fine rhinitis: “Have you ever had hay fever?” and “Have
you ever suffered - in the absence of a cold - from an
itchy stuffy or runny nose and/or swollen, itchy eyes?”
The question “Have you ever had an itchy rash, which
was coming and going for at least six months?” was used
as an indicator of eczema.
The second interview was conducted 2 to 4 weeks
after delivery. It provided information on delivery date,
gestational age (weeks), mode of delivery (spontaneous
vaginal delivery, after induction vaginal delivery,
Cesarean section), gender of the offspring, maternal and
child health status, maternal and household smoking
during pregnancy period (yes, no), maternal use of anti-
biotics during pregnancy, and history of vaginal infec-
tions/pelvic conditions during pregnancy. The birth date
was utilized to assign the season at birth based on pollen
seasons in South Carolina [fall (September, October,
November) and spring (March, April, May)]. The non-
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February) and summer (June, July, and August).
The third and fourth interviews were based on the
International Study of Asthma and Allergies in Child-
hood (ISAAC) questionnaire [23] and ascertained
asthma-like symptoms at ages 6 and 12 months. The re-
call period was restricted to either the previous 6 or
12 months. In the case that a 6 month interview was
performed at 7 months after delivery, the mother was
still asked to report on only the period of time before
the child turned age 6 months. Additionally, the inter-
view collected information on duration of breastfeeding
(weeks) as well as information on smoking in the house
in the last 6 months (yes, no). At 6 and 12 months, the
following question was asked for ascertaining the differ-
ent respiratory infections of the child in the last
6 months: “In the last 6 months, was a doctor’s diagnosis
made in your child of (yes, no): (1) pneumonia, (2)
wheezy bronchitis, (3) infectious bronchitis, or (4)
middle-ear infection.”
Blood and breast milk collection and preparation
Women were asked to provide one blood sample before
delivery and one breast milk sample about two weeks
after delivery. Ten milliliters of blood were taken by
venipuncture from each woman in the last trimester of
pregnancy (range: 0 to 13 weeks before delivery, median:
3 weeks before delivery). All serum samples were col-
lected in sterile tubes (BD Vacutainer ®, 10 mL), and
centrifuged within one hour of collection at 3,500 revo-
lutions per minute (rpm) for 10 minutes (min) at 4
degrees Celsius (°C). The separated serum samples were
stored at −20°C then after 24 hours were transferred to
−80°C where the samples were stored until needed for
analysis.
Each participant expressed approximately 15 mL of
breast milk, using an electric breast pump provided by
the study, on average three weeks after delivery (range
1–8 weeks). All women followed a detailed breast milk
collection protocol. Women were asked to collect breast
milk during the morning and after putting the baby to
the breast. The nipple and surrounding breast area were
cleaned with sterile wipes prior to breast milk collection.
All breast milk samples were collected in sterile plastic
bottles (Medela 80 ml [2.7 oz]). Research staffs picked
the breast milk sample up at the participant residence.
Within one hour of collection, all samples were trans-
ferred to sterile centrifuges tubes and spun at 2,900 rpm
for 10 minutes at 4°C. Fat was removed; centrifugation
and fat removal steps were repeated until all fat was
taken out. Finally, the cell pellet was removed. The iso-
lated whey and serum were aliquoted and stored in
a −80°C freezer until preparation for immunoassays.Immuno-assay protocols
The concentrations of IL-1β, IL-4, IL-5, IL-6, CXCL8,
IL-10, IL-12(p70), IL-13, CXCL10, CCL11, and IFN-γ in
both serum and whey were assayed using the Bioplex
Protein Array system (BioRad, Bio-Rad Laboratories,
Inc., Hercules, CA). This multiplexes system allows for
the assessment of several immune markers in the same
Biorad custom-made bioplex pro human cytokine, che-
mokine, and growth factor multiplex plate. ELISAs (en-
zyme-linked immunosorbent assay) were used to
determine concentrations of IgA (Immunology Consul-
tants Laboratory) and TGF-β1 (R&D Systems). To acti-
vate latent TGF-β1 to immuno-reactive TGF-β1
detectable by the Quantikine TGF-β1 immunoassay, we
followed the manufacture procedure [24]. All assays
were conducted according to the manufacturer’s kit
instructions [24-26]. Each sample, including standards
and the blank, was assayed in duplicate. A total of 15
multiplexes were performed to determine the concentra-
tion of the immune markers in serum and whey. For
each plate we determined the limit of detection (LOD)
by multiplying the standard deviation of the blank by
three. Those samples that had concentrations below the
detection limit were assigned a value corresponding to
half the LOD.
Outcome variable
Asthma like-symptoms (AS) in infants were ascertained
prospectively at ages 6 and 12 months by the ISAAC
questionnaire. AS included the following items [options:
yes, no, if not stated otherwise]: 1) has your child had
wheezing or whistling in the chest in the last 6 months?
2) how many attacks of wheezing has your child had in
the last 6 months? (options: more than twelve; three to
twelve; one to two; none – dichotomized to one or more
vs. none) 3) has your child been unwell when breathing
in or making noise when doing so in the last 6 months;
and 4) has your child suffered from a shortness of breath
in the last 6 months? Any positive answer to one of
these four questions was considered as presence of AS.
Exposures
The main exposures were immune markers levels in ma-
ternal serum before delivery and in whey. The immune
markers included in the analyses were the following:
Type-1/pro-inflammatory cytokines/chemokines (IFN-γ,
CXCL10, IL-6, and CXCL8), Type-2/pro-allergic cyto-
kines/chemokines (IL-5 and IL-13), T-regulatory/anti-
inflammatory cytokine (TGF-β1) and IgA levels. The
concentrations were recorded in pg/mL, except for IgA,
which was measured in mg/mL. Due to their distribu-
tions, we categorized all immune markers into quartiles
except for IL-5 in whey and IgA in serum, which were
dichotomized.
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To investigate the association of serum and whey im-
mune markers, intra-class and Spearman correlation coef-
ficients were estimated. The following confounders were
controlled in the statistical analyses. Maternal characteris-
tics included race, age at pregnancy, smoking during
pregnancy, household cigarette use at ages 6 and
12 months, maternal history of asthma, eczema, and rhin-
itis, consumption of antibiotics during pregnancy, and va-
ginal infections/pelvic conditions during pregnancy.
Offspring characteristics comprised of gender, any re-
spiratory infections at ages 6 and 12 months, and season
of birth. Indicators of respiratory infections during in-
fancy included a doctor’s diagnosis of pneumonia, wheezy
bronchitis, infectious bronchitis, and middle-ear infection.
Gestational age, maternal education, pet exposure, pre-
conception body mass index, and mode of delivery were
removed from the models because they were not
confounding.
Log-linear regression was used to test whether im-
mune markers were associated with AS at age 6 months
and with ever AS in the first year of life (supplemental
material). Generalized estimating equations were applied
to predict repeated occurrence of AS in infants at ages 6
and 12 months. Adjusting for within-participant effects
using the regular maximum likelihood method, we
started with an unstructured covariance matrix, which
requires the least amount of constraints. Other covari-
ance matrices, including compound symmetry and auto-
regressive, were considered and most of the models
presented the same QIC goodness of fit statistic [27].
A total of 16 adjusted models (8 for each serum and
whey markers) were run to analyze the effect of immune
markers on AS. Initially, we considered analyzing serum
and whey immune markers in one model; however,
this led to collinearity problems [28], since most of
the immune markers presented correlations above
0.5 (e.g., CXCL10 and CXCL8 in whey r = 0.68). In
addition, the possibility that whey’s immune markers are
in the ‘causal pathway’ between immune markers in serum
and AS cannot be tested with simple regression models
since these models do not allow for intervening variables.
Controlling for an intervening variable as a confounder
would split the initial association between the risk factor
and the outcome into two associations, destroying the
‘causal pathway’. For these reasons, we assessed all im-
mune markers in serum and whey separately. We detected
that the immune markers had non-linear relations with
AS. We tested for linearity by cross-tabulating groups with
increasing immune marker levels with the outcome. We
therefore analyzed all the immune markers (with the
exception of IL-5 in whey and IgA in serum) by
comparing risk ratio (RR) estimates for AS, contrast-
ing the upper quartiles with the lowest quartile (lowconcentration) as reference group. IL-5 in whey and IgA in
serum were dichotomized (high versus low) by using the
median as a cut off since their distributions were skewed
and small proportion of individuals with AS information in
the lowest quartile (reference group). We estimated the
95% confidence interval (CI) and also presented p-values to
identify associations that survive penalizing for multiple
testing.
We are interested in understanding whether both im-
mune markers in maternal serum and whey are primar-
ily associated with AS in offspring. Given the time
sequence of serum preceding whey, this could shed light
on whether pre- or post-natal cytokine levels are the cul-
prit for asthma-like symptoms in infancy. To address
this question using one correlated cytokine variable, we
created high and low concentration combinations of
IL-13 and IL-5 using the median as a cut-off point (these
cytokines were chosen because their individual concentra-
tions were significantly associated with AS). The resulting
levels were categorized as follows: 1) high levels in serum/
high levels in whey, 2) low levels in serum/high levels in
whey, and 3) low levels in serum/low levels in whey. Since
the combination “high levels in serum/low levels in whey”
had two or less observations, we did not consider this com-
bination for the analysis.
All confounders were simultaneously entered as indi-
cator variables into the generalized mixed models. A
backward elimination process was used to retain con-
founders in the final model: confounders were those
which changed the effect of the main association by
10% or more when omitting this factor from the model.
To address confounding due to respiratory infections
during infancy, we examined any of the four markers of
respiratory infections and wheezy bronchitis as confoun-
ders. In addition, we also ran models excluding infants
who had both wheezy bronchitis and AS. To adjust for
multiple testing, we applied a separate false discovery
rate (p = 0.05) for serum and whey immune markers
[29]. All statistical analyses were performed using SAS
version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Of 178 women who participated, 161 provided maternal
blood and 115 breast milk samples (98 provided both
prenatal blood sample and breast milk sample). Most of
the participants were Caucasian (73.5%) and highly edu-
cated. A history of maternal eczema was reported by
9.1%, a history of asthma by 27.4%, and a history of rhin-
itis by 48.2% (Table 1). About 5% reported smoking dur-
ing pregnancy, and 45% had a vaginal infections/pelvic
conditions during pregnancy.
Proportions of asthma-like symptoms were 34.8% and
32.4% at ages 6 and 12 months, respectively (Table 2).
About 24% (age 6 months) and 49% (age 12 months) of
Table 1 Characteristics of the participants
Variables Pre-delivery Breast milk All samples
serum n=115 N=178
n=161 n (%) N (%)
n (%)
Maternal race
African American (AA) 38 (25.5) 20 (17.5) 44 (26.5)
Caucasian or Other 111 (74.5) 94 (82.5) 122 (73.5)
Maternal education
Less than high school 16 (10.8) 9 (7.9) 20 (12.1)
Some college 37 (24.8) 25 (21.9) 41 (24.7)
College graduate 48 (32.2) 36 (31.6) 52 (31.3)
Graduate school 48 (32.2) 44 (38.6) 53 (31.9)
Mode of delivery
Spontaneous vaginal delivery 54 (40.3) 47 (41.6) 61 (40.7)
After induction vaginal delivery 49 (36.6) 38 (33.6) 56 (37.3)
Cesarean section 31 (23.1) 28 (24.8) 33 (22.0)
Sex of the infant
Male 70 (50.4) 55 (48.7) 79 (50.9)
Female 69 (49.6) 58 (51.3) 76 (49.1)
Maternal smoking during pregnancy
Non-smoker 127 (94.8) 105 (93.7) 141 (94.6)
Smoker 7 (5.2) 7 (6.3) 8 (5.4)
Maternal history of allergy
Asthma 42 (28.6) 32 (28.1) 45 (27.4)
Rhinitis 68 (46.3) 60 (52.6) 79 (48.2)
Eczema 13 (8.8) 10 (8.8) 15 (9.1)
Season of child’s birth
Fall 32 (22.7) 23 (20.4) 34 (21.7)
Spring 32 (22.7) 27 (23.9) 34 (21.7)
Summer 30 (21.3) 26 (23.0) 37 (23.6)
Winter 47 (33.3) 37 (32.7) 52 (33.1)
Gestational use of antibiotics 29 (18.0) 32 (27.8) 34 (19.1)
Vaginal infections/pelvic conditions during pregnancy*
Yes 60 (44.8) 49 (43.4) 67 (44.7)
No 74 (55.2) 64 (56.6) 83 (55.3)
Mean (n; 5%, 95%)
Maternal age during pregnancy 29.2 30.9 29.2
(143; 19.4, 38.9) (111; 21.7, 38.9) (158; 19.4, 38.9)
Gestational age (weeks) 39.0 39.0 39.0
(133; 36.0, 41.0) (112; 36.0, 41.0) (149; 36.0, 41.0)
* Including urinary tract infection, vaginitis or vaginosis, genital warts, genital herpes, gonorrhea, syphilis, chlamydia, trichomoniasis, yeast infection, and group B
Streptococcus infections.
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infants at age 6 months and 17% at age 12 months pre-
sented both AS and any type of respiratory infection
(data not shown). Four out of 137 infants at age
6 months and 5 out of 102 infants at age 12 months had
both AS and wheezy bronchitis. At ages 6 months, 8.0%(11/137) of the infants and 14.7% (15/102) at 12 months
had both mid ear infection and AS. Infectious bronchitis
was present in approximately 1% (6 months) and 2%
(12 months) of the infants.
Immune markers IL-12(p70), IL-4, IL-10, IL-1β, and
CCL11 in serum and in whey were not considered in the
Table 2 Prevalence of asthma-like symptoms and respiratory infections at ages 6 and/or 12 months (N= 140)
Asthma-like symptoms (% (n/total)) 6 months 12 months 6 or 12 months 6 and 12 months
Wheezing 15.2 (21/138) 13.7 (14/102) 20.7 (29/140) 4.3 (6/140)
One or more wheezing attacks 31.8 (35/110) 26.9 (21/78) 39.0 (48/123) 6.5 (8/123)
Felt unwell and made noise when breathing 13.1 (18/137) 15.7 (16/102) 21.4 (30/140) 2.9 (4/140)
Shortness of breath 2.2 (3/136) 4.9 (5/102) 5.8 (8/139) 0 (0/139)
Combined asthma-like symptoms
Any asthma-like symptom 34.8 (48/138) 32.4 (33/102) 47.9 (67/140) 10.0 (14/140)
Child respiratory infections
Pneumonia 0 (0/137) 3.9 (4/102) 2.9 (4/140) 0 (0/140)
Wheezy bronchitis 3.7 (5/137) 7.8 (8/102) 8.6 (12/140) 0.7 (1/140)
Infectious bronchitis 0.7 (1/137) 1.9 (2/102) 2.1 (3/140) 0 (0/140)
Mid-year infection 22.6 (31/137) 47.1 (48/102) 42.1 (59/140) 14.3 (20/140)
Combined child respiratory infections
Any respiratory infection 24.1 (33/137) 49.0 (50/102) 44.3 (62/140) 15.0 (21/140)
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detectable values (low or undetectable concentrations)
were obtained. The concentrations of CXCL10 and
CXCL8 were higher in whey than in serum samples. In
addition, most immune markers in maternal serum and
whey were moderately to highly intra-correlated (0.35 -
0.66; Table 3), CXCL8 and IgA in serum and whey were
negatively correlated (−0.44 and −0.43, respectively).
Regarding the correlation between immune markers in
maternal serum, we found that most of the markers
were moderately correlated with a spearman correlation
coefficient range of 0.36 to 0.80 (supplemental material,
Additional file 1: Table E1). The Th2 cytokines in serum,
IL-13 and IL-5, had a correlation of 0.77 (p <0.0001),
however in whey, IL-13 and IL-5 were not correlated. In
addition, in whey IL-13 and IgA in whey were negatively
correlated (spearman correlation coefficient =−0.21;
p = 0.03; Additional file 1: Table E2).
The crude analyses of the repeated measurements of
AS indicated that IL-5, IL-13, CXCL10, and IgA in both
maternal serum and whey had a significant influence on
AS (data not shown). After adjusting for confounders (in-
cluding any respiratory infections, Table 2), all the afore-
mentioned immune markers in both serum and whey
remained significant risk markers for AS (Figure 1;
Table 4). For instance, infants in the highest quartile of
the serum IL-13 distribution had three times the risk of
AS compared to infants in the first quartile. Chil-
dren exposed to the highest IL-13 level in whey had
a significantly higher relative risk for occurrence of
AS (RR = 4.18). Regarding IL-5, the risk for AS was 4.34
times higher than the risk in the lowest level in serum,
while in whey, children with a high level (dichotomized) of
this cytokine had twice the risk of AS compared to infants
in the lower level. Regarding IgA, after adjusting forconfounders, children exposed to breast milk with the high-
est quartile of IgA in whey had a significantly lower relative
risk for occurrence of AS (RR=0.23; p=0.02). In contrast,
children of mothers with the high serum IgA (dichoto-
mized) had 2.09 times higher relative risk (Figure 1; Table 4)
compared to children of mothers with the low serum IgA.
Infants exposed to the highest and the third quartile level
of TGF-β1 in whey had a lower relative risk for occurrence
of AS (RR=0.3 and 0.26, respectively). Among the con-
founders, maternal history of eczema and household
cigarette use at ages 6 and 12 months doubled the risk for
AS (data not shown).
Regarding the occurrence of asthma in the first six
months and cumulative in the first 12 months, adjusted
analyses of ever AS in infancy indicated that IL-5 and
IL-13 in both maternal serum and whey, and TGF-β1
and IgA in whey had a significant influence on AS (sup-
plemental material; Additional file 1: Table E3). In
addition, IL-5, IL-13, IgA in both maternal serum and
whey, and TGF-β1 in whey were associated with AS in
the first 6 months of life (Additional file 1: Table E4).
We compared the associations between immune mar-
kers in maternal serum and whey with repeated mea-
surements of AS at ages 6 and 12 months before and
after statistically controlling for respiratory infections,
wheezy bronchitis, and after excluding those who pre-
sented both wheezy bronchitis and AS. After controlling
for wheezy bronchitis the RRs were similar to the
adjusted risk ratios presented in Figure 1. Also after ex-
cluding children who had both wheezy bronchitis and
AS, the RRs did not change. Hence, controlling for re-
spiratory infections or excluding children with wheezy
bronchitis did not essentially affect the associations of
IL-5, IL-13, CXCL10, IgA, and TGF-β1 in both serum
and whey with AS.
Table 3 Proportion of quantified immune markers, their distribution and correlations between maternal pre-delivery




























IL-13 50.0 (80) 1.12 0.02, 9.50 70.4 (81) 0.46 0, 5.31 0.66 <0.0001 0.58 <0.0001
CXCL8 30.5 (39) 2.11 0.42, 8.49 79.8 (67) 5.60 0.40, 265.07 0.02 0.87 −0.44 <0.0001
IL-6 30.5 (39) 2.11 1.06, 27.17 30.9 (26) 1.06 0.21, 20.64 0.36 0.002 0.31 0.007
IL-5 70.3 (90) 1.06 0.03, 2.29 73.8 (62) 0.10 0, 2.12 0.64 <0.0001 0.72 <0.0001
IFN-γ 55.3 (89) 3.89 1.06, 174.22 40.9 (47) 1.59 1.07, 102.53 0.50 <0.0001 0.48 <0.0001
CXCL10 97.5 (157) 169.18 1.91, 2956.89 93.9 (108) 270.25 1.91, 10184.64 0.35 0.002 0.26 0.007
TGF-β1 89.3 (75/84) 23078.87 7.7, 45143.40 93.0 (80/86) 600.88 7.7, 1823.90 0.55 <0.0001 0.31 0.006
IgA 100 (86/86) 5.10 1.98, 8.53 100 (89/89) 4.35 0.13, 2931.48 0.07 0.18 −0.43 <0.0001
#A total of 15 multiplexes were performed to determine the concentration of the immune markers in serum and whey. For each plate we determined the limit of
detection (LOD) by multiplying the standard deviation of the blank by three. Those samples that had concentrations below the detection limit were assigned a
value corresponding to half the LOD.
†Immune markers IL-12(p70), IL-4, IL-10, IL-1β, and CCL11 in serum and in whey were not analyzed since high proportion of non-detectable values were obtained.
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of low or high levels of IL-13 and IL-5 immune markers
in serum or whey were associated with repeated AS in
infants (Table 5). Compared to low levels of IL-13 in
both serum and whey, low levels of IL-13 in serum andFigure 1 Adjusted effects of immune markers in maternal
serum and in breast milk whey on asthma-like symptoms at
ages 6 and 12 months: a repeated measurement analysis.
* Immune markers (except for IL-5 in whey and IgA in serum) were
categorized into quartiles using the first quartile (lowest values) as
reference. IL-5 in whey and IgA in serum were dichotomized. The
risk ratios represent the highest level of the immune marker (4th
quartile) compared to the lowest level. IL-5, IL-13, CXCL10, IgA, and
TGF-β1 serum and whey were adjusted for child’s sex, maternal age
during pregnancy, maternal race, smoking during pregnancy, vaginal
infections during pregnancy, maternal history of asthma, eczema,
and rhinitis, consumption of antibiotics during pregnancy, season of
child’s birth, any respiratory infection during infancy, and household
cigarette use at ages 6 and 12 months. † Gestational age, maternal
education, pet exposure, preconception maternal body mass index,
and mode of delivery were removed from the models because they
were not confounding.high levels in whey showed an increased relative risk for
AS (IL-13: RR = 5.62). The combination of high levels of
IL-5 in both serum and whey were marginally associated
with AS compared to the low levels (RR = 2.13, p = 0.07).
Discussion
This is the first study to simultaneously examine the ef-
fect of immune markers in both maternal serum and
breast milk whey on asthma-like symptoms in infants at
ages 6 and 12 months. Results of the repeated measure-
ment analyses suggest for individual immune markers
that there is an increased risk of AS for higher IL-5 and
IL-13 levels in maternal serum collected at the end of
the pregnancy and whey. However, a combination of low
levels of IL-13 in serum and high levels in whey
increased the risk of AS. Higher individual concentra-
tions of IgA and TGF-β1 in whey diminished the relative
risk of AS, whereas higher IgA levels in maternal serum
posed a risk.
With regards to selection bias, participation in studies
during pregnancy and infancy depends on volunteering
and a high level of dedication to study requirements. We
enrolled 231 women and received breast milk or blood
samples from 178 participants (77.1%). A strength of this
study is the high compliance with clinical data collection
since 78% (140/178) of the participants provided infor-
mation on the child’s AS either at ages 6 or 12 months.
We could not detect any association between the pres-
ence of AS symptoms and the likelihood of providing
maternal blood/breast milk samples. However, our data
show a potential selection. Based on the South Carolina
Pregnancy Risk Assessment Monitoring System
(PRAMS) survey data from 2006–2007, 21% of women
Table 4 Adjusted effects of immune markers in maternal serum and in whey on AS at ages 6 and 12 months
Immune markers† Immune markers in maternal serum before delivery Immune markers in breast milk whey
RR* p-value RR* p-value
Type-1/pro-inflammatory cytokines/chemokine (pg/mL)
CXCL10
4th quartile (high) 2.30 0.01 1.31 0.46
3rd quartile 1.57 0.13 0.43 0.03
2nd quartile 0.96 0.90 0.68 0.28
Type-2/pro-allergic cytokines/chemokines (pg/mL)
IL-13
4th quartile (high) 3.02{ 0.004 4.18{ 0.001
3rd quartile 2.20 0.03 1.12 0.13
2nd quartile 1.10 0.78 1.91 0.83
IL-5
4th quartile (high) 4.34 0.001 2.24{ 0.01
3rd quartile 1.85 0.18 n/a n/a
2nd quartile 2.27 0.05 n/a n/a
T-regulatory/anti-inflammatory cytokine (pg/mL)
TGF-β1
4th quartile (high) 0.53 0.11 0.31{ 0.01
3rd quartile 0.64 0.31 0.26 0.002
2nd quartile 0.39 0.08 1.13 0.75
#Immunoglobulin A (mg/mL)
4th quartile (high) 2.09 0.04 0.23{ 0.02
3rd quartile n/a n/a 0.54 0.14
2nd quartile n/a n/a 1.09 0.83
* Immune markers (except for IL-5 in whey and IgA in serum) were categorized into quartiles using the first quartile (lowest values) as reference. IL-5 in whey and
IgA in serum were dichotomized. IL-5, IL-13, CXCL10, IgA, and TGF-β1 serum and whey were adjusted for child’s sex, maternal age during pregnancy, maternal
race, smoking during pregnancy, vaginal infections during pregnancy, maternal history of asthma, eczema, and rhinitis, consumption of antibiotics during
pregnancy, season of child’s birth, any respiratory infection during infancy, and household cigarette use at ages 6 and 12 months.
# Secretory immunoglobulin A in whey but not in serum.
† Gestational age, maternal education, pet exposure, and mode of delivery were removed from the models because they were not confounding.
{ The overall effect of the quartiles was statistically significant after applying a false discovery rate (adjusted p value < 0.05).
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study 31% reported to graduate from college. It is known
that women who smoked during pregnancy are more
likely to be unmarried and have less than a high school
education [30]. In our study 5% reported to smoke dur-
ing pregnancy, whereas 16% of pregnant women in SC
smoked during the last three months of pregnancy in
2008 [30]. However, since we adjusted for smoking dur-
ing pregnancy in our explanatory models, the potential
selection bias was diminished. In addition, maternal edu-
cation did not confound the association between im-
mune markers in both maternal serum and whey and
asthma-like symptoms. Hence, the influence also of this
potential selection bias is minimal.
Additionally, collecting duplicate measurements of each
cytokine is likely to have improved the accuracy of the
measurements. We also report similar findings for allcytokines measured in serum and milk whey. When com-
parable associations with AS are observed for cytokines
obtained in both whey and serum samples, it is less likely
that these findings are due to measurement errors or that
they are due to chance. Hence, statistically significant find-
ings for IL-5 and IL-13 in serum are corroborated by com-
parable results in whey and vice versa. Moreover, since
levels of immune markers in whey may vary over time
[31-34], we tested whether the immune mediators’ levels
correlated with the interval of collection after birth. None
of the immune markers were correlated with the time of
milk collection, which is an agreement with a recent re-
view on breast milk immune markers [35]. Regarding the
dates of maternal blood sample collection, most immune
markers except for IFN-γ were not correlated with the
number of days of blood collection before delivery. Since
IFN-γ was not associated with AS, there was no need to
Table 5 Adjusted effects of immune markers in maternal
serum/breast milk whey on AS at ages 6 and 12 months
Immune marker† aRR* p-value
(95% CI)
IL-13
High serum/high whey 1.62 (0.70, 3.75) 0.25
Low serum/high whey 5.62 (2.25, 14.03) 0.0002
Low serum/low whey Reference
IL-5
High serum/high whey 2.13 (0.93, 4.88) 0.07
Low serum/high whey 0.77 (0.23, 2.57) 0.68
Low serum/low whey Reference
* IL-5 and IL-13 were adjusted for child’s sex, maternal age during pregnancy,
maternal race, smoking during pregnancy, pelvic infections during pregnancy,
maternal history of asthma, eczema, and rhinitis, consumption of antibiotics
during pregnancy, season of child’s birth, any respiratory infection during
infancy, and household cigarette use at ages 6 and 12 months.
† Gestational age, maternal education, pet exposure, and mode of delivery
were removed from the models because they were not confounding.
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in the other explanatory models.
Furthermore, interviews and collection of breast milk
and venous blood and their chemical analyses were con-
ducted independently. Therefore, there is no reason to as-
sume that the information provided by the participants
has distorted our results. In the statistical analyses we con-
trolled for potential confounders. However, we did not
control for breastfeeding duration since the immune mar-
kers are intervening variables between breastfeeding and
asthma-like symptoms (a chain of responses). It is not ap-
propriate to split a chain of responses up into their ele-
ments and assess them individually since the elements of
one chain are dependent on one another. The product of
breastfeeding duration (median: 4 weeks) and immune
markers in breast milk was also not considered given that
such a product will produce large uncertainty since im-
mune markers were only measured once and their level
may change during the course of breastfeeding [35]. It is
possible that other unmeasured confounders may predis-
pose the child to develop asthma-like symptoms in in-
fancy such as the exposure to house dust mites, area of
residence, day care attendance, and parity. Genetic suscep-
tibility, environmental factors, and geographical location
of the host may explain the discrepancies found between
our study and others [36,37]. Finally, regarding the sample
size, this study is one of the larger investigations. Only five
studies reported so far on immune markers in whey had
sample sizes of 100 or more [35].
To estimate the effect of infections on AS, we con-
ducted four alternate approaches: (1) not excluding
children with AS and wheezy bronchitis; (2) using
wheezy bronchitis as a confounder; (3) using the four re-
spiratory infections variable as one confounder, and (4)excluding all cases with wheezy bronchitis. The results
of these approaches showed similar associations; hence a
misclassification of asthma-like symptoms as respiratory
infections is unlikely to explain our findings. There is no
consensus in the literature as to what AS in childhood
represents [38,39]. It is generally considered that AS
early in life are related to respiratory viruses [39], but
not allergies. However, these symptoms in children, al-
though related to viruses initially, may become allergic
[39]. Hence, AS in infancy are more likely to reflect an
unspecific response of the respiratory system to external
antigenic challenges in general (locus minoris resisten-
tiae), rather than a specific response to a specific type of
antigenic challenge.
Another limitation of our study is that we ran separate
models for each immune marker. The drawback of this
approach is that the effect of each cytokine was not
adjusted for other proteins in serum and whey. However,
the adjustment for other proteins would have presented
collinearity issues, which would have biased the risk esti-
mates. One way to address this issue is to determine la-
tent patterns or factors that incorporate multiple
immune markers. However, this approach will not pro-
vide specific information for the various markers. After
adjusting for multiple testing using the false discovery
rate, the statistical effects of IL-13 in serum, and IL-5,
IL-13, IgA, and TGF-β1 in whey remained significant
(Table 4).
Regarding the median concentration of immune mar-
kers in maternal serum, IFN-γ, IgA, and TGF-β1 were
similar to other maternal serum studies [35], but IL-5,
IL-6, and IL-13 were lower. Regarding the concentrations
of the immune markers detected in whey, the median of
IgA, TGF-β1, CXCL10, and IFN-γ were comparable to
other breast milk studies recently reviewed by Agarwal
et al. [35]. The other cytokines (IL-5, IL-6, and IL-13)
and chemokine (CXCL8) levels in whey were lower, al-
though they still fell within the range reported by other
studies. Previous studies have reported that TGF-β1
measurement in plasma is preferable compared to serum
because a major part of this marker is released by plate-
lets during clotting [40]. However, for complete release
of TGF-β1 from serum, we incubated serum overnight at
2 - 8°C before centrifugation and then followed the acti-
vation manufacture procedure [24].
Type-2 cytokines
Our results suggest that two Type-2 markers (IL-5 and
IL-13) were risk markers for the occurrence of AS in
infants. It is known that Th2 cells orchestrate allergic in-
flammation through the release of the Type-2 cytokines
IL-5 and IL-13 [41]. In particular, IL-5 has been linked
to eosinophil-mediated inflammatory response, IL-4 and
IL-13 in the isotype switching of B-cells to IgE
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mucus secretion [42-44]. Thus, IL-13 and IL-5 cytokines
are considered to play a prominent role in the patho-
physiology of asthma [45]. This is the first study to dem-
onstrate a link of IL-5 and IL-13 in maternal serum and
milk whey with AS in infants.
Type-1 cytokines/chemokines
The Type-1 cytokines are responsible for cell-mediated im-
munity and phagocytes-dependent protective responses.
Cytokines/chemokines produced by Th1 cells include IFN-
γ, IL-12(p70), and CXCL10.
Our results suggest that the exposure to high levels of
CXCL10 (IP-10) during gestation may predispose the
fetus to asthma-like symptoms in infancy, however the
third quartile level of this cytokine was protective. To
date, no studies have looked at the effect of this marker
in maternal serum and in whey on asthma-like symp-
toms in infants, creating the necessity for further assess-
ment. In an additional analysis, we explored whether an
imbalance of Th1 and Th2 immune markers (ratios of
Th2 to Th1 cytokines) affects the occurrence of AS in
infancy. No association of any ratio with AS was found.
T-regulatory/anti-inflammatory cytokines and IgA
We identified that the highest quartiles of TGF-β1 and
IgA in whey were related to a 69% and 77% diminished
probability of AS, respectively. Some previous studies
reported that differences in secretory immunoglobulin A
(sIgA) in breast milk did not affect the development of
childhood allergies [46-49]. However, other studies have
demonstrated that higher levels of sIgA [50] and TGF-
β1 [51] in breast milk are protective against the develop-
ment of allergy [52,53], and wheezing during infancy
[54]. Our finding on TGF-β1 is in agreement with the
results reported by Oddy et al., since they found that the
risk of wheeze was lower when TGF-β1 was increased
(long breastfeeding and medium-high TGF-β1 levels
compared with short breastfeeding and low TGF-β1
level).
Interestingly, higher concentrations of IgA (geometric
mean: 12.88 mg/ml) in whey than in serum (geometric
mean: 4.73 mg/ml, Table 3) suggest that whey IgA is lo-
cally derived from the mammary glands [35]. The nega-
tive correlation found between IgA in serum and whey,
may be due to the fact that the predominant IgA isotype
presented in serum is IgA1, whereas in whey it is pre-
dominantly IgA2 [55,56]. A limitation is that our ELISA
kit did not distinguish these two isotypes. Moreover, the
source of circulating IgA in predominantly bone marrow
plasma cells while the source of secretory IgA is from
mucosal cells [57].
It is known that maternal IgA does not cross the pla-
centa and its levels are low in cord blood [58]. Hence, itwas surprising to find that higher maternal serum IgA
(probably reflecting higher IgA1) posed an increased risk
for asthma-like symptoms in the infant. We do not
know how to explain this association. To the best of our
knowledge, no previous study has found such associ-
ation, and therefore, this finding needs further evalu-
ation. During early infancy, the baby’s intestinal
production of IgA is low [59]. It is considered that the
maternal IgA provides the protection against environ-
mental pathogens. Maternal IgA seems to stimulate the
offspring production of IgA, preventing the child from
developing allergies [60].
In this study, both maternal serum and whey immune
markers (IL-13 and IL-5) increased the risk of AS in the
offspring from South Carolina. Given that immune mar-
kers in maternal serum and whey are correlated
(Table 3), the results suggests that the child had a similar
exposure to immune markers in late gestation (0 to
13 weeks before delivery) and postnatal period. This
brings us to the question of whether exposure during
late gestation or after birth is more influential for AS. It
is believed that antenatal events (including dietary nutri-
ents, microbial products, and cigarette smoking) may
play a role in the development of allergic diseases [61].
Prescott et al. found that the capacity of the fetus to pro-
duce IL-13 and IL-10 was directly related to the levels of
these cytokines produced by the mother in response to
fetal antigens, implying that the level of immune reactiv-
ity at the feto-maternal interface may influence the level
and pattern of evolving fetal immune responses [61]. If
there is passage across the placenta, the infant’s contact
with specific immune markers in breast milk is likely
not to be a de novo exposure [36]. Our results propose
that having the combination of low IL-13 in serum and
high in whey was significantly associated to AS, signify-
ing that high levels of this marker in whey pose a risk
for AS. Since gestational and postnatal exposures to im-
mune factors may contribute to an infant’s risk of devel-
oping immune-mediated disorders [62], it is important
to decipher the role of both prenatal and post-natal im-
mune factors in the development of respiratory immune
responses of the infant.
Conclusion
In summary, this is the first longitudinal study to investi-
gate the effect of immune markers in maternal serum
before delivery and in whey on the occurrence of AS in
infants. Our study is one of few with a sample size of
100 and more [36]; and it seems that both maternal
serum and whey provide a multitude of immune mar-
kers that affect the occurrence of AS in infants. Our
results support previous findings showing a protective
effect of IgA and TGF-β1 against the occurrence of AS
in children. Although IL-5 and IL-13 are known to be
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study has demonstrated associations with AS previously.
Therefore, we were surprised to find that these cytokines
in serum and whey were strong risk markers. These
effects warrant further investigations. When only breast
milk is investigated, it seems as if milk cytokines IL-5
and IL-13 have adverse effects. However, similar im-
mune exposure during gestation and via milk suggests
that both increase AS among infants. Consequently, fu-
ture studies need to take maternal immune markers in
serum into consideration when assessing the risk of im-
mune markers in breast milk.
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